Tag: Roche

Roche’s Personalised Medicine Rozlytrek Approved in Japan

roche
Roche announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients with neurotrophic tyrosine receptor ...

Roche’s Polivy Granted FDA Accelerated Approval Status

Roche announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) fo...

Roche to Submit Xofluza Flu Prevention Data with Global Health Authorities

clinical-trials
Roche announced that the phase III BLOCKSTONE study, conducted by Shionogi & Co., Ltd., met its primary endpoint showing that people exposed to a household member with influenza (flu) and treated ...

Roche Presents Data from Across Its Breast Cancer Portfolio

Roche presents new and updated results from a number of abstracts highlighting studies including the treatment of both PD-L1-positive triple-negative and HER2-positive breast cancer at the 2019 ASCO A...

Roche and GE Healthcare Establish NAVIFY Tumor Board 2.0

Roche announced the release of NAVIFY Tumor Board 2.0, the first collaboration product from partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other pati...

Genentech and Parvus in Worldwide Collaboration

Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has entered i...

Roche Spins Out New Biotech Nimble Therapeutics

Roche has spun out Nimble Therapeutics, a new biotech that starts life with $10 million in financing and chemical synthesis technology developed at Roche, along with the team that helped create it. Fi...

Ex-Roche Chen Appointed New Everest Medicines CCO

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China ...

Roche and Genentech’s Ocrevus Won a Recommendation from England’s NICE

Patients with Multiple Sclerosis (MS) will have routine access to a drug that can slow disability under a deal struck between NHS England and the manufacturer Roche, paving the way for its approval by...

FDA Approved Roche Kadcyla

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Kadcyla® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HE...

Roche Announced Another Extension of its $4.3 billion Offer for Spark

Roche on Friday  announced another extension of its $4.3 billion offer for gene therapy specialist Spark Therapeutics, this time until June 3, saying a review by U.S. authorities is taking longer than...

Roche Q1 Sales Rose 9%

Swiss drug major Roche reported that its group sales for the first-quarter rose 9 percent to 14.83 billion Swiss francs from last year's 13.58 billion francs, while it was up 8 percent at constant exc...

Roche and Novartis are Among the Biggest Spenders on R&D in 2018

Over the past decade Roche and Novartis consistently spent more on R&D than other big pharma groups, evaluate.com reports. Abbvie and Astrazeneca have added to their budgets. The world’s 12 big...

FDA Approved Use of Tecentriq with Chemotherapy

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) tr...

European Approval for Roche’s Treatment for Rare Disease

Roche today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by pro...

EC Approved Roche’s Hemlibra

First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis, in a prospective intra-patient comparison. Roche today announced that the European Commission has ap...